Wockhardt is running out of options
Faced with a cash crunch, the Mumbai-based drug maker has only its research to fall back on. Will it yield a blockbuster?
August 24, 2023•10 min
0
August 24, 2023•10 min
0
More in Business
Business
Infra.Market is a hamster wheel looking at a make-or-break IPO
The construction material supply firm’s scale and profitability may appear shiny, but hide a stark truth. Its use of equity to fund working capital is playing with fire when bigger fish are eyeing its business.
You may also like
Internet
Why quick delivery of medicines will be difficult to scale
Quick-commerce apps are likely to run into regulations and poor order volumes as they try to grow this business.
Internet
Why is Swiggy catching flak for its latest quick-delivery promise?
The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.
Business
For Sun Pharma’s Dilip Shanghvi, specialty drugs remain the magic bullet
Specialty drugs are fast becoming a lucrative market globally. And India’s largest drugmaker has done well to make the most of this opportunity so far. But it’s too soon to rest easy.